NSE Symbol: | BSE Code: | ISIN: | Sector:

  • Add to Portfolio
  • Add to Watchlist
  • Add to Alert
  • Add to Message
Add to Portfolio
Change Change %
-7.55 -1.09%

Updated:22 Jan, 2021, 15:54 PM IST

Change Change %
-7.50 -1.08%

Updated:22 Jan, 2021, 16:01 PM IST

Aarti Drugs (ADL), incorporated in 1984, is engaged in the business of manufacturing generic bulk actives, advanced intermediates and specialty chemicals. The company is part of $265 million Aarti Group of Industries.

ADL manufactures drugs in therapeutic segments such as anti–arthritis, anti–fungal, antibiotics, anti–diabetic, anti–cholinergic, sedatives, anti–depressant, anti–diarrhea and anti–inflammatory. The company?óÔé¼Ôäós manufacturing facilities are located at Tarapur and Sarigam. The drug major has received ISO 9001:2000 certifications for quality management.


API– ADL manufactures active pharmaceuticals ingredients (API) and steroids. Under API, it manufactures products such as aceclofenac, clopidogrel bisulphate, ketoconazole, metformin HCl, hydroxyzine pomoate, ketoconazole, irbesartan and many more. The company manufactures steroids such as hydrocortisone sodium succinate sterile, hydrocortisone acetate, hydrocortisone and hemisuccinate.

Pharma Intermediates– The company manufactures pharma intermediates for irbesartan, Zolpidem Tartrate, Tamsulosin HCL, Leflunomide and Levocetirizine

Speciality Chemicals– Under this, the company manufactures products such as benzene sulphonyl chloride, benzene sulphonamide, diphenyl sulphone, N–ethyl toluene sulphonamide, ethyl toluene sulphonate, para chloro benzene sulphonamide, benzene sulfonyl hydrazide and many more.

The company?óÔé¼Ôäós R&D centre at Turbhe near Mumbai, focuses on developing new value added molecules. This facility is recognised by Department of Science and Industrial Research and Government of India.

The company also undertakes contract manufacturing for its customers.

ADL's products are exported to over 85 countries across the globe. It has received Export House Status recognition of from Government of India. The company has clientele namely Sanofi–Aventis, Merck, Teva , Searle, Pfizer, Bayer and Clariant to name a few.

New Development

Aarti Drugs' R&D programs are currently focused on new products amongest non–steroidal NSAID compounds, antiparasitic, calciun antagonist, antianginal, antidiabetics, antdepressant and many more. The company has also planned to work on speciality chemicals and agro chemicals.

Listen to the latest songs, only on